Ambiente
Aurisco sets Goals and Plans for Carbon Neutrality by 2027 and Zero Emissions by 2030
Aurisco serves global markets with over 25 years' experience in the development and cGMP manufacture of Active Pharmaceutical Ingredients. With 6 R&D centers, 3 FDA inspected sites and building its 4th site in China , and sales offices in USA, Portugal , India and Brazil , the company focuses on complex products for the most demanding customers in the most regulated markets. With a broad portfolio of complex generic APIs, the company is broadening its offer from small molecules to peptides and oligonucleotides and offering innovators an IP safe and cGMP and ESG compliant environment for research, development and manufacturing of their innovative molecules. With over 80 patents filled worldwide and 250 scientists, the company pays special attention to IP, innovation and sustainability.
Being Ecovadis ranked, Aurisco has joined the SBTi, M2030 and the Sustainable Procurement Pledge. Aurisco was the first pharmaceutical company in
China to pass a RX360 supply chain security inspection and has been audited by the Pharmaceutical Supply Chain Initiative (PSCI), a group of pharmaceutical and healthcare companies who share a vision of better social, health, safety and environmental outcomes in the communities where they buy. www.aurisco.com.
Photo - https://mma.prnewswire.com/media/2281617/Aurisco_Pharmaceutical.jpg
Logo - https://mma.prnewswire.com/media/2142124/Aurisco_25th_Anniversary_Logo.jpg
Rafael Antunes
Vice-President Business Development – Europe
+351 919 387 143
rafael@aurisco.com
www.aurisco.com
View original content:https://www.prnewswire.co.uk/news-releases/aurisco-sets-goals-and-plans-for-carbon-neutrality-by-2027-and-zero-emissions-by-2030-301993510.html